Daniel J. Lenihan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniel J. Lenihan has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Douglas B. Sawyer
Maine Medical Center, Portland, Maine, USA
3 shared publications Eitan A. Friedman
A Department of Medicine, Division of Cardiovascular Medicine , Vanderbilt University School of Medicine , Nashville , TN , USA
3 shared publicationsCarrie Geisberg Lenneman
Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee
2 shared publications- Daniela Cardinale
Cardioncology Unit, European Institute of Oncology, I.R.C.C.S., Milan, Italy
2 shared publications Douglas B. Sawyer
Maine Medical Center, Portland, Maine
2 shared publications- Douglas B. Sawyer
Department of Medicine, Cardiovascular Division, Vanderbilt University, Nashville, TN
2 shared publications
Latest Publications
- 1 November 2017
- Published by Elsevier in Clinical Biochemistry
- Vol. 50 (16-17) , 889-895
Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease
- 1 November 2017
- Published by Elsevier in Clinical Biochemistry
- Vol. 50 (16-17) , 889-895
Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease
- Open Access
- 1 June 2017
- Published by Springer Nature in Cardio-Oncology
- Vol. 3 (1) , 1-6
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective was to evaluate the incidence of CAEs associated with PI and recognize risk factors for developing events. This was a descriptive analysis of 96 patients with multiple myeloma who received bortezomib (n = 44) or carfilzomib (n = 52). We compared the cumulative incidence of CAEs using a log rank test. Patient-related characteristics were assessed and multivariate analysis was used to identify risk factors for developing CAEs. PI-related CAEs occurred in 21 (22%) patients. Bortezomib-associated CAEs occurred in 7 (16%) patients while carfilzomib-associated cardiac events occurred in 14 (27%) patients. The cumulative incidence of CAEs was not significantly different between agents. Events occurred after a median of 67.5 days on PI therapy. Heart failure was the most prevalent event type. More patients receiving carfilzomib were monitored by a cardiologist. By multivariate analysis, a history of prior cardiac events and longer duration of PI therapy were identified as independent risk factors for developing CAEs. AEs were common in patients receiving PIs. Choice of PI did not impact the cumulative incidence of CAEs. Early involvement by a cardiologist in patients at high risk for CAEs may help to mitigate the frequency and severity of CAEs.
- 1 June 2017
- Published by Springer Nature in Cardio-Oncology
- Vol. 3 (1) , 1-6
Open AccessCardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective was to evaluate the incidence of CAEs associated with PI and recognize risk factors for developing events. This was a descriptive analysis of 96 patients with multiple myeloma who received bortezomib (n = 44) or carfilzomib (n = 52). We compared the cumulative incidence of CAEs using a log rank test. Patient-related characteristics were assessed and multivariate analysis was used to identify risk factors for developing CAEs. PI-related CAEs occurred in 21 (22%) patients. Bortezomib-associated CAEs occurred in 7 (16%) patients while carfilzomib-associated cardiac events occurred in 14 (27%) patients. The cumulative incidence of CAEs was not significantly different between agents. Events occurred after a median of 67.5 days on PI therapy. Heart failure was the most prevalent event type. More patients receiving carfilzomib were monitored by a cardiologist. By multivariate analysis, a history of prior cardiac events and longer duration of PI therapy were identified as independent risk factors for developing CAEs. AEs were common in patients receiving PIs. Choice of PI did not impact the cumulative incidence of CAEs. Early involvement by a cardiologist in patients at high risk for CAEs may help to mitigate the frequency and severity of CAEs.
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2)
Cardio-oncology Related to Heart Failure
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2)
Cardio-oncology Related to Heart Failure
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2) , 409-416
Current Concepts of Cardiac Amyloidosis
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2) , 409-416
Current Concepts of Cardiac Amyloidosis
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2)
Cardio-Oncology—A Rapidly Evolving and Expanding Field of Medicine
- 1 April 2017
- Published by Elsevier in Heart Failure Clinics
- Vol. 13 (2)
Cardio-Oncology—A Rapidly Evolving and Expanding Field of Medicine
- Open Access
- 1 February 2017
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 2 (1) , 54-55
Cardio-Oncology
- 1 February 2017
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 2 (1) , 54-55
Open AccessCardio-Oncology
- Open Access
- 1 December 2016
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 1 (7) , 576-586
A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure
- 1 December 2016
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 1 (7) , 576-586
Open AccessA Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure
- 25 October 2016
- Published by Springer Nature
- p. 297-315
Biomarkers in Specific Disease States: Cardio-Oncology
- 25 October 2016
- Published by Springer Nature
- p. 297-315
Biomarkers in Specific Disease States: Cardio-Oncology
- 1 October 2016
- Published by Taylor & Francis in Amyloid
- Vol. 23 (4) , 242-248
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis
Background: Cardiac amyloidosis is an infiltrative cardiomyopathy that is challenging to diagnose. We hypothesized that the novel biomarkers hepatocyte growth factor (HGF), galectin-3 (GAL-3), interleukin-6 (IL-6), and vascular endothelial growth factor (VEGF) would be elevated in cardiac amyloidosis and may be able to discriminate from non-cardiac systemic amyloidosis or other cardiomyopathies with similar clinical or morphologic characteristics. Methods: Patients were selected from the Vanderbilt Main Heart Registry according to the following groups: (1) amyloid light-chain (AL) cardiac amyloidosis (n = 26); (2) transthyretin (ATTR) cardiac amyloidosis (n = 7); (3) left ventricular hypertrophy (LVH) (n = 45); (4) systolic heart failure (n = 42); and (5) non-cardiac systemic amyloidosis (n = 7). Biomarkers were measured in stored plasma samples. Biomarkers' discrimination performance in predicting AL cardiac amyloidosis (i.e., Concordance index) was reported. A survival analysis was used to explore the relationship between HGF levels and mortality among AL cardiac amyloidosis patients. Results: HGF levels were markedly elevated in patients with AL cardiac amyloidosis (median = 622, interquartile range (IQR): 299–1228 pg/mL) compared with the other groups, including those with non-cardiac systemic amyloidosis (median = 134, IQR: 94–163 pg/mL, p < 0.001). HGF was not a specific marker for ATTR amyloidosis. Gal-3 was elevated in all groups with amyloidosis but could not differentiate between those with and without cardiac involvement. There was no difference in IL-6 or VEGF between those with AL cardiac amyloidosis compared to other groups (p = 0.13 and 0.057, respectively). Conclusions: HGF may be a specific marker that distinguishes AL cardiac amyloidosis from other cardiomyopathies with similar clinical or morphologic characteristics. Further studies are necessary to determine whether HGF levels predict the likelihood of survival.
- 1 October 2016
- Published by Taylor & Francis in Amyloid
- Vol. 23 (4) , 242-248
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis
Background: Cardiac amyloidosis is an infiltrative cardiomyopathy that is challenging to diagnose. We hypothesized that the novel biomarkers hepatocyte growth factor (HGF), galectin-3 (GAL-3), interleukin-6 (IL-6), and vascular endothelial growth factor (VEGF) would be elevated in cardiac amyloidosis and may be able to discriminate from non-cardiac systemic amyloidosis or other cardiomyopathies with similar clinical or morphologic characteristics. Methods: Patients were selected from the Vanderbilt Main Heart Registry according to the following groups: (1) amyloid light-chain (AL) cardiac amyloidosis (n = 26); (2) transthyretin (ATTR) cardiac amyloidosis (n = 7); (3) left ventricular hypertrophy (LVH) (n = 45); (4) systolic heart failure (n = 42); and (5) non-cardiac systemic amyloidosis (n = 7). Biomarkers were measured in stored plasma samples. Biomarkers' discrimination performance in predicting AL cardiac amyloidosis (i.e., Concordance index) was reported. A survival analysis was used to explore the relationship between HGF levels and mortality among AL cardiac amyloidosis patients. Results: HGF levels were markedly elevated in patients with AL cardiac amyloidosis (median = 622, interquartile range (IQR): 299–1228 pg/mL) compared with the other groups, including those with non-cardiac systemic amyloidosis (median = 134, IQR: 94–163 pg/mL, p < 0.001). HGF was not a specific marker for ATTR amyloidosis. Gal-3 was elevated in all groups with amyloidosis but could not differentiate between those with and without cardiac involvement. There was no difference in IL-6 or VEGF between those with AL cardiac amyloidosis compared to other groups (p = 0.13 and 0.057, respectively). Conclusions: HGF may be a specific marker that distinguishes AL cardiac amyloidosis from other cardiomyopathies with similar clinical or morphologic characteristics. Further studies are necessary to determine whether HGF levels predict the likelihood of survival.